Education
About Us
Working with TipRanks
Follow Us
Soleno Therapeutics Inc (SLNO)
NASDAQ:SLNO
SLNO Stock Chart & Stats
$43.98
-$1.55(-3.35%)
At close: 4:00 PM EST
$43.98
-$1.55(-3.35%)
Day’s Range― - ―
52-Week Range$37.95 - $90.32
Previous CloseN/A
Volume118.06K
Average Volume (3M)1.38M
Market Cap
$2.27B
Enterprise Value$2.12B
Total Cash (Recent Filing)$498.93M
Total Debt (Recent Filing)$2.81M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Mar 11, 2026EPS Estimate
0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.47
Shares Outstanding53,710,026
10 Day Avg. Volume1,332,458
30 Day Avg. Volume1,383,363
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)7.37
Price to Sales (P/S)0.00
P/FCF Ratio-26.05
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue21.47
Enterprise Value/Gross Profit21.87
Enterprise Value/Ebitda-31.95
Forecast
1Y Price Target
$107.22Price Target Upside143.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)4.26
Revenue Forecast (FY)$484.50M
Bulls Say, Bears Say
Bulls Say
Prescriber Growth And ReimbursementAnalyst notes steady expansion of the prescriber base and improving reimbursement coverage, supporting broader patient access and sustained demand.
Profitability And Cash FlowAnalyst highlights that the company achieved profitability and positive cash flow during the commercial launch, reinforcing financial stability for further expansion.
Revenue OutlookAnalyst modestly raised the 2026 revenue forecast, indicating stronger expected sales momentum as commercial uptake continues.
Bears Say
Addressable Patient LimitationsAnalyst warns certain patient groups and those on specific medications are unlikely candidates and that contraindications for some conditions narrow the addressable market.
Operating Cost PressureAnalyst moderately raised the 2026 operating expense forecast, signaling higher expected costs that could weigh on margins and free cash flow.
Uptake Uncertainty And Retention HeadwindsAnalyst flags slowing new patient starts, rising discontinuations and insurance access hurdles, alongside safety‑report driven disruption, which could constrain future treatment uptake.
Soleno Therapeutics News
SLNO FAQ
What was Soleno Therapeutics Inc’s price range in the past 12 months?
Soleno Therapeutics Inc lowest stock price was $37.95 and its highest was $90.32 in the past 12 months.
What is Soleno Therapeutics Inc’s market cap?
Soleno Therapeutics Inc’s market cap is $2.27B.
When is Soleno Therapeutics Inc’s upcoming earnings report date?
Soleno Therapeutics Inc’s upcoming earnings report date is Mar 11, 2026 which is in 34 days.
How were Soleno Therapeutics Inc’s earnings last quarter?
Soleno Therapeutics Inc released its earnings results on Nov 04, 2025. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.058 by $0.412.
Is Soleno Therapeutics Inc overvalued?
According to Wall Street analysts Soleno Therapeutics Inc’s price is currently Undervalued.
Does Soleno Therapeutics Inc pay dividends?
Soleno Therapeutics Inc does not currently pay dividends.
What is Soleno Therapeutics Inc’s EPS estimate?
Soleno Therapeutics Inc’s EPS estimate is 0.71.
How many shares outstanding does Soleno Therapeutics Inc have?
Soleno Therapeutics Inc has 53,710,026 shares outstanding.
What happened to Soleno Therapeutics Inc’s price movement after its last earnings report?
Soleno Therapeutics Inc reported an EPS of $0.47 in its last earnings report, beating expectations of $0.058. Following the earnings report the stock price went down -26.594%.
Which hedge fund is a major shareholder of Soleno Therapeutics Inc?
Currently, no hedge funds are holding shares in SLNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Soleno Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$107.22 (143.79% Upside)
$107.22 (143.79% Upside)
Blogger Sentiment
Bearish
SLNO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 785.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.3%
Last 30 Days ▲ 11.7%
Last 30 Days ▲ 11.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.74%
12-Months-Change
Fundamentals
Return on Equity
-20.66%
Trailing 12-Months
Asset Growth
102.18%
Trailing 12-Months
Company Description
Soleno Therapeutics Inc
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
SLNO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented significant positive developments, including strong revenue growth, profitability, and broad payer coverage for VYKAT XR. However, these were tempered by challenges such as increased discontinuation rates and the impact of a short seller report affecting market momentum.View all SLNO earnings summariesSLNO Stock 12 Month Forecast
Average Price Target
$107.22
▲(143.79% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---